Efficacy and Safety of Sintilimab Plus Anlotinib for PD-L1–Positive Recurrent or Metastatic Cervical Cancer: A Multicenter, Single-Arm, Prospective Phase II Trial

No combined immunotherapy and antiangiogenic therapy have been investigated in exclusively programmed death-ligand 1 (PD-L1)–positive advanced cervical cancer (CA). We investigated the efficacy and safety of sintilimab plus anlotinib as second-line or later therapy for PD-L1–positive recurrent or me...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Qin, Wang, Junjie, Sun, Yang, Lin, Yibin, Liu, Jing, Zhuo, Yanhong, Huang, Zhangzhou, Huang, Songhua, Chen, Ying, Chen, Li, Ke, Meifang, Li, Li, Li, Zirong, Pan, Junping, Song, Yanwen, Liu, Rongqiang, Chen, Chuanben
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2022
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9148684/
https://www.ncbi.nlm.nih.gov/pubmed/35192397
http://dx.doi.org/10.1200/JCO.21.02091

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9148684/
https://www.ncbi.nlm.nih.gov/pubmed/35192397
http://dx.doi.org/10.1200/JCO.21.02091

Ejemplares similares